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ABSTRACT  
 
Background: High-density lipoprotein (HDL) containing apolipoprotein E (apoE-rich 
HDL) represents only a small portion of plasma HDL. Reliable methods for determining 
and isolating apoE-rich HDL have not been well studied. 
Methods: We established a novel analytical method for apoE-rich HDL using 
polyethylene glycol and a cation-exchange column (PEG-column method). Furthermore, 
we examined biochemical correlates of apoE-rich HDL-cholesterol (HDL-C) in 36 
patients who underwent coronary computed tomographic angiography. 
Results: Our PEG-column method demonstrated high reproducibility (coefficient of 
variation <3.52%) and excellent linearity up to 15 mg/dl for apoE-rich HDL-C levels. 
Isolated apoE-rich HDL exhibited a larger diameter (14.8 nm) than apoE-poor HDL 
(10.8 nm) and contained both apoE and apoA-I. ApoE-rich HDL-C levels correlated 
significantly with triglycerides (r=−0.646), LDL size (r=0.472), adiponectin (r=0.476), 
and other lipoprotein components. No significant correlation was obtained with the 
coronary calcium score. Multiple regression analysis revealed that plasma triglycerides 
and adiponectin levels remained significant independent predictors of apoE-rich 
(adjusted R2=0.486) but not apoE-poor HDL-C. 
Conclusions: The PEG-column method demonstrated, to various degrees, significant 
correlations between HDL subfractions and several lipid-related biomarkers involved in 
an atherogenic lipoprotein profile. Our separation technique for apoE-rich HDL is 
useful to clarify the role of apoE-rich HDL in atherosclerosis. 
 
Keywords: HDL subfraction, Atherogenic lipoprotein, Chromatography 
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1. Introduction 
Numerous clinical and epidemiological studies have shown that decreased levels of 
HDL-cholesterol (HDL-C) represent an independent risk factor for coronary artery 
disease [1–3]. HDL has been recently proposed to possess multiple biological functions 
including anti-inflammatory, anti-oxidative, and vasodilatory activities, as well as its 
traditional role in reverse cholesterol transport [4–9]. HDLs are, however, a highly 
heterogeneous group and differ in lipid and protein composition, size, hydrated density, 
and electrophoretic mobility [3,6,10]. Therefore, individual HDL subpopulations might 
play specific roles in the multiple anti-atherogenic activities associated with HDL 
overall. 
HDLs containing apolipoprotein E (apoE-rich HDL) represent an HDL subclass that 
accounts for up to 10% of the total HDL in adult human plasma [11,12]. In animal 
models, apoE-rich HDL is referred to as HDL1 or HDLc induced by dietary cholesterol 
and can deliver cholesterol to the liver directly via interaction with the LDL receptor 
[10,13,14]. ApoE-rich HDL also exhibits several atheroprotective properties including 
promotion of cholesterol efflux [5], stimulation of endothelial heparin sulfate synthesis 
[15], inhibition of platelet aggregation [16,17], and maintenance of arterial elasticity 
[18]. These fundamental findings suggest that apoE-rich HDL might serve as a useful 
biomarker for cardiovascular risk estimation. 
In a clinical study reported by Wilson et al., the level of plasma apoE-rich HDL was 
decreased in patients with coronary heart disease compared to control subjects [19]. 
Proteomic analysis revealed an increased level of apoE in an HDL3 subfraction isolated 
from subjects with established coronary artery disease [20]. However, there are 
relatively few studies that have investigated the clinical significance of apoE-rich HDL 
levels, mainly because no conventional analytical methods are currently available for its 
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assessment. Simple and rapid methods are therefore required for lipoprotein analysis in 
clinical settings. 
A method used widely for the separation and fractionation of plasma lipoproteins 
involves ultracentrifugation; however, it has been noted that some apoE could easily 
dissociate from lipoprotein particles during this process [21,22]. In addition, 
ultracentrifugation is time-consuming and requires a large sample volume as well as 
great care to precisely recover lipoproteins from the centrifuge tube. Another critical 
problem with ultracentrifugation is that the density range of apoE-rich HDL overlaps 
that of dense LDL, lipoprotein(a), and other HDLs [23]. These findings indicate that 
ultracentrifugation has marked limitations as a tool for plasma lipoprotein analyses. 
In contrast, Chiba et al. reported a useful method for determining the serum 
concentration of apoE-rich HDL-C, which is calculated as the difference in the 
cholesterol levels of total and apoE-deficient HDL [11]. This method is based on double 
precipitation procedures wherein the total HDL fraction is separated from whole serum 
using polyethylene glycol (PEG) precipitation and the apoE-deficient HDL is prepared 
using a dextran sulfate-phosphotungstate-Mg2+ reagent. More recently, Takahashi et al. 
established a homogeneous assay [12] allowing sequential assessment of total, 
apoE-containing, and apoE-deficient HDL that might potentially promote clinical and 
epidemiological studies on apoE-rich HDL. However, the double precipitation and the 
homogeneous methods are unlikely to be useful for investigating biological functions 
and pathophysiological roles of apoE-rich HDL because they lack the ability to isolate 
apoE-rich HDL. 
Based on these considerations, we aimed to develop a novel method for determining 
the cholesterol levels of apoE-rich HDL and a technique for isolating apoE-rich HDL 
from serum or plasma using a combination of PEG precipitation with cation-exchange 
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chromatography (PEG-column method). To further validate the utility of our method, 
we examined clinical and biochemical correlates of apoE-rich HDL-C levels in patients 
who underwent coronary computed tomographic (CT) angiography. 
 
2. Materials and methods 
2.1. Precipitation method for total HDL separation 
To eliminate apoB-containing lipoproteins from whole serum or plasma samples, we 
used the PEG method described by Chiba et al. [11]. In brief, a 13% PEG6000 (Wako 
Pure Chemical, Osaka, Japan) solution was mixed with the same volume of serum or 
plasma. The mixed solutions were left for at least 10 min at room temperature and 
centrifuged at 8,000 × g for 5 min to obtain supernatants containing total HDL (PEG 
supernatant). Each of the PEG supernatants was passed through a 0.20-μm filter 
(Sartorius Stedim Biotech, Goettingen, Germany) before being applied to a 
cation-exchange column. 
 
2.2. Cation-exchange chromatography 
The high performance liquid chromatography (HPLC) system (Tosoh Bioscience, 
Tokyo, Japan) consisted of an AS-8020 sampler, CCPM-II and CCPS pumps, and a 
UV-8020 detector. A SC-8020 system controller (Tosoh Bioscience) was used for 
instrument regulation. A µ7 Data Station (System Instruments, Tokyo, Japan) was used 
for data collection and analysis.  
Separation of apoE-rich HDL and apoE-poor HDL was accomplished using a 
cation-exchange column (HiTrap SP HP, 1 mL, GE Healthcare, Uppsala, Sweden). The 
column was equilibrated with buffer A (10 mM MOPS, pH 7.2) containing 40 mM 
magnesium acetate prior to sample injection. Increasing concentrations of Mg2+ in 
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buffer A were used to determine the effect of Mg2+ on the separation of HDL 
subfractions. The retained fraction, corresponding to apoE-rich HDL, was eluted with 
buffer B (10 mM MOPS, 1.0 M sodium acetate, and 0.01% Triton X100, pH 7.2). Buffers 
were pumped at a flow rate of 1.0 ml/min; 100% buffer A for 2 min, 100% buffer B for 3 
min, and then 100% buffer A for 4 min. Typically, 8 μl of total HDL, isolated by the PEG 
precipitation method, were injected into the column at intervals of 9 min per sample, 
and the column effluent was mixed with an enzymatic reagent for cholesterol at a flow 
rate of 0.3 ml/min. The absorbance at 550 nm was monitored continuously after the 
enzymatic reaction at 37C in a reactor coil (Teflon, 30 m × 0.4 mm id). For the 
determination of apolipoprotein distribution, the column effluent was collected in 0.4-ml 
fractions with a fraction collector (Bio-Rad Laboratories, Berkeley, CA, USA), and 
analyzed by an enzyme-linked immunosorbent assay (ELISA). 
 
2.3. Isolation and purification of apoE-HDL  
A total HDL fraction containing no other serum proteins was prepared by 
ultracentrifugation. Briefly, the PEG supernatant was adjusted to a density of 1.21 kg/l 
by adding solid NaBr, and 3.2 ml of the resulting solution was placed in a polycarbonate 
centrifuge tube. After centrifugation in an Optima MAX Ultracentrifuge (Beckman 
Coulter, Brea, CA, USA) with a fixed-angle TLA 110 rotor at 543,000 × g for 15 h at 16C, 
1.0 ml of the top layer was recovered, pooled, and dialyzed against 10 mM MOPS (pH 
7.2) at 4C. The dialyzed top fraction was adjusted to a final 40 mM Mg2+ concentration 
by adding solid magnesium acetate, diluted with buffer A, and 30 ml (10 mg/dl total 
HDL-C) was applied to a cation-exchange column (HiTrap SP HP, 5 mL, GE Healthcare). 
After washing the column with buffer A, bound HDL (apoE-rich HDL) was eluted with 
buffer B containing no detergent, collected, and concentrated using an Amicon Ultra 
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centrifugal filter with a molecular weight cutoff of 30 kDa (Merck Millipore, Darmstadt, 
Germany). In some experiments, PEG in the unbound HDL (apoE-poor HDL) was 
removed using an anion-exchange column (HiTrap DEAE FF, 1 mL, GE Healthcare) 
equilibrated with buffer A. The purified apoE-rich and apoE-poor HDL fractions were 
dialyzed against 10 mM Tris-HCl (pH 7.2) containing 0.15 M NaCl, and used for 
subsequent analyses of apolipoproteins and particle size.  
 
2.4. Determination of LDL and HDL mean particle sizes 
The particle size distribution of lipoproteins was analyzed using the gel-permeation 
HPLC method. Briefly, the separation of lipoproteins was carried out with a Superose 
6HR column (300 × 10 mm, GE Healthcare) at a flow rate of 0.5 ml/min with 10 mM 
Tris-HCl (pH 7.2) containing 0.15 M NaCl, followed by an on-line enzymatic cholesterol 
detection [24,25]. Elution times of the observed peaks on a chromatogram were 
converted to particle sizes using a linear calibration curve of the logarithm of the 
particle sizes plotted against the elution times corresponding to LDL and HDL in a 
calibrator [26]. The mean particle sizes of LDL and HDL in the calibrator were 
determined at Skylight Biotech (Tokyo, Japan) to be 25.3 and 11.3 nm, respectively.  
 
2.5. ELISA 
ApoA-I, apoA-II, and apoE were measured by a noncompetitive sandwich ELISA. 
Polystyrene 96-well microtiter plates (Corning Inc., Corning, NY, USA) were coated 
with 100 µl/well anti-apoA-I (1:2000, BM2577, Acris Antibodies, San Diego, CA, USA), 
anti-apoA-II (1:1000, 12A-G1b, Academy Bio-Medical Company, Houston, TX, USA), or 
anti-apoE (1:2000, GtxHu-039-D, ImmunoReagents, Raleigh, NC, USA) antibodies 
dissolved in 10 mM phosphate-buffered saline (PBS) (pH 7.2) for 12 h at 4C. The coated 
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plate was washed with washing buffer (10 mM PBS, 0.01% Tween 20, pH 7.2). Then, the 
calibrators and samples diluted with 5 mM Tris-HCl (pH 7.2) containing 0.1% casein 
(Wako) and 0.02% Tween 20 were added to each well (100 µl). The plate was incubated 
on a microplate shaker (Mikura, Lower Beeding, UK) for 1.5 h at room temperature and 
washed with washing buffer. For detection, anti-apoA-I (11A-G2b), anti-apoA-II 
(12A-G1b), and anti-apoE (50A-G1b, Academy Bio-Medical Company) antibodies were 
labeled with biotin using a Biotin Labeling Kit-SH (Dojindo, Kumamoto, Japan). Each 
of the biotin-labeled detection antibodies (0.5 µg/ml), dissolved in the reaction buffer 
containing 5 mM Tris-HCl (pH 7.3), 0.1% casein, 0.01% Tween 20, and 0.15 M NaCl, was 
added to each well (100 µl) and the plate was incubated for 1.5 h. After washing the 
plate, 0.5 µg/ml of a streptavidin-horseradish peroxidase conjugate (Vector Laboratories, 
Burlingame, CA, USA) diluted with the reaction buffer was added to each well (100 µl), 
and the plate was incubated for 0.5 h. After washing the plate, color was developed by 
the addition of 100 µl/well SureBlue TMB Microwell Peroxidase Substrate (Kirkegaard 
& Perry Laboratories, Gaithersburg, MD, USA), followed by 100 µl/well of 1.0 M HCl to 
stop the reaction. Absorbance was measured at 450 nm using a microplate reader 
(Model 680, Bio-Rad Laboratories). 
 
2.6. Precision and linearity  
For the reproducibility study, two PEG supernatants with high (88 mg/dl) and low 
(39 mg/dl) levels of HDL-C were analyzed in 10 replicates to calculate within-day 
imprecision values. To test the range of linearity for our method, a PEG supernatant 
separated from the whole serum of a healthy normolipidemic subject [214 mg/dl total 
cholesterol (TC), 46 mg/dl triglycerides (TG)] was serially diluted with buffer A and 24 
µl of the diluted sample was applied to the column.  
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2.7. Method comparison study 
For comparison with the PEG-column method, the double precipitation method was 
carried out according to the procedure reported previously [11]. First, total HDL was 
separated from whole serum using PEG precipitation as described in Section 2.1. Next, 
apoE-deficient HDL was prepared from whole serum using the DS-PT-Mg reagent 
(0.18% dextran sulfate (Wako), 0.3% sodium phosphotungstate (Nacalai Tesque, Kyoto, 
Japan), and 0.1 M MgCl2 (Wako)) instead of the 13% PEG solution. The serum 
apoE-rich HDL-C concentration was calculated as the difference in cholesterol levels of 
total and apoE-deficient HDL. 
 
2.8. Study subjects 
For comparison of apoE-rich HDL-C obtained from human subjects by the double 
precipitation and the PEG-column methods, 31 apparently healthy Okayama 
University students (male/female, 7/24), aged 21–23 years, were recruited. In addition, 
we evaluated the clinical significance of apoE-rich HDL-C level measurements using 
plasma samples from 36 patients who underwent coronary CT angiography at the 
Okayama Heart Clinic (Okayama, Japan). Coronary CT scanning was performed using 
a 64-slice multi-detector instrument (Siemens Healthineers, Erlangen, Germany), and 
the coronary calcium score (CCS) was calculated automatically. The total CCS, which 
was calculated as the sum of the CCS values in each lesion of four coronary arteries (left 
main, left anterior descending, left circumflex, and right coronary artery), was used for 
data analysis. The presence of coronary artery stenosis was defined as 50% or greater 
narrowing in luminal diameter. The plasma levels of TC, HDL-C, and TG were 
measured routinely at the hospital laboratory using standard enzymatic methods. 
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LDL-cholesterol (LDL-C) was calculated from the formula of Friedewald et al. [27]. 
Plasma adiponectin and leptin were measured using the Human Total 
Adiponectin/Acrp30 Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA) and 
the Human Leptin Assay kit (Immuno-Biological Laboratories, Fujioka, Japan), 
respectively. Other lipoprotein-associated measures were determined at our laboratory 
using methods described in Section 2. 
The examination procedure complied with the rules of the Declaration of Helsinki 
[28] and the study was approved by the Institutional Ethics Committee for Human 
Research of Okayama University Graduate School of Medicine, Dentistry, and 
Pharmaceutical Sciences. All subjects provided their informed consent before entering 
the study.  
 
2.9. Statistics 
Data analyses were performed using SPSS version 17.0 software (IBM, Armonk, NY, 
USA). Continuous variables are presented as means ± SD. Correlations between 
variables were assessed by Pearson's or Spearman’s correlation coefficients (r value). 
Multiple regression analysis was used to identify the factors influencing HDL 
subfractions. The Shapiro-Wilk test was used to evaluate the normality of distribution 
of the variables. Skewed data were log-transformed to create a more normal 
distribution. A P value less than 0.05 was considered statistically significant. 
 
3. Results 
3.1. Effect of Mg2+ concentration in buffer A on HDL separation 
We first studied the effect of Mg2+ concentration in the running buffer A on HDL 
separation. For cholesterol detection, almost all HDL passed through the 
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cation-exchange column when using buffer A without Mg2+, whereas the amount of 
bound HDL increased gradually and reached a plateau at 20–40 mM Mg2+ (Fig. 1A, C). 
For apoE detection, 70% of the apoE in HDL (HDL-apoE) passed through the column at 
0 M Mg2+ and bound HDL reached a plateau at 20–40 mM Mg2+ (Fig. 1B, D). 
Approximately 90% of the HDL-apoE was eluted in peak 2 using buffer A containing 40 
mM Mg2+. Therefore, 40 mM Mg2+ was considered sufficient and suitable to separate the 
apoE-rich HDL subfraction from total HDL. 
 
3.2 Apolipoproteins and particle size of purified apoE-rich HDL 
Purified apoE-rich HDL from a healthy and normolipidemic subject (70 mg/dl 
HDL-C) was analyzed by 12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) under reducing conditions. The proteins were stained by 
CBB R-250. As shown in Fig. 2A, bound HDL (purified apoE-HDL) contained mainly 
both apoE and apoA-I whereas unbound HDL contained apoA-I but lacked apoE. The 
bound HDL particles were larger in size compared to unbound HDL (14.2 vs. 11.2 nm), 
as demonstrated by gel-permeation HPLC analysis (Fig. 2B). The lipid and 
apolipoprotein composition of apoE-rich HDL from 4 healthy and normolipidemic 
subjects are summarized in Table 1. The ratio of apoE (mg/dl) to apoA-I (mg/dl) was 1.09 
± 0.315 for apoE-rich HDL and 0.010 ± 0.011 for apoE-poor HDL. 
 
3.3. Precision and linearity 
Our PEG-column method produced good within-day imprecision values (coefficients 
of variation, CVs) of 0.29% for total HDL-C (88.2 mg/dl), 0.33% for apoE-poor HDL-C 
(81.6 mg/dl), and 0.61% for apoE-rich HDL-C (6.6 mg/dl) in the sample with high HDL-C. 
In the sample with low HDL-C, CVs for total HDL-C (39.3 mg/dl), apoE-poor HDL-C 
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(37.6 mg/dl), and apoE-rich HDL-C (1.7 mg/dl) were 0.53, 0.45, and 3.52%, respectively. 
To define the assay linearity for HDL subfractions, the chromatographic peak area 
was plotted as a function of the expected cholesterol values of diluted samples. Good 
linear correlations were obtained up to at least 200 mg/dl for total HDL-C, 180 mg/dl for 
apoE-poor HDL, and 15 mg/dl for apoE-rich HDL-C (Fig. 3). 
 
3.4. Comparison between the PEG-column and double precipitation methods 
We compared our PEG-column method with the double precipitation method for 
determining apoE-rich HDL-C in 31 serum samples from healthy volunteers. The 
scatter plot in Fig. 4A shows that the cholesterol levels of apoE-rich HDL obtained by 
our method correlated with those generated by the double precipitation method (r = 
0.724), albeit significantly underestimated their content (3.2 ± 1.3 vs. 5.7 ± 2.8 mg/dl). 
Conversely, the levels of HDL-apoE were more strongly correlated with those of 
apoE-rich HDL-C using our method (r = 0.894) than by the double precipitation method 
(r = 0.525) (Fig. 4B). 
 
3.5. Clinical and biochemical correlates of apoE-rich HDL-C 
Clinical and biochemical characteristics of the studied patients are listed in Table 2. 
HDL size and leptin levels were significantly higher in females compared to males. 
There was no significant difference in apoE-rich HDL-C levels between patients with 
and without >50% stenosis (3.4 ± 1.5 and 3.5 ± 1.4 mg/dl, respectively). Simple 
correlations of apoE-poor and apoE-rich HDL-C levels with various clinical and 
biochemical variables are summarized in Table 3. Both HDL subfractions were similarly 
correlated with several variables owing to a strong positive correlation (r = 0.901) 
between apoE-poor and apoE-rich HDL-C. CCS was not significantly correlated with 
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either HDL fraction. However, plasma TG and adiponectin levels remained significant 
independent predictors of apoE-rich HDL, but not apoE-poor HDL, in multiple 
regression models (Table 4). Only LDL size remained an independent predictor of the 
apoE-rich/apoE-poor HDL-C ratio. 
 
4. Discussion 
Our novel PEG-column method successfully isolated plasma apoE-rich HDL and 
determined its cholesterol level precisely and rapidly. This meets quality specifications 
for the clinical evaluation of apoE-rich HDL as well as for basic research on plasma 
lipoproteins. 
Several previous studies reported separation techniques of apoE-rich HDL using 
approaches based on heparin- [14-19] or immunoaffinity [22,29], reliant upon the 
well-known apoE heparin-binding domain [30]. For example, Weisgraber and Mahley 
separated apoE-HDL from total HDL (density: 1.063-1.21 kg/l) using a 
heparin-sepharose affinity column equilibrated with NaCl-Tris buffer (50 mM NaCl, 5 
mM Tris, pH 7.4) containing 25 mM MnCl2 [14]. However, we considered that a 
Mn2+-free buffer might avoid the interference of Mn2+ with enzymatic detection of 
cholesterol [31], as well as the issues of generating waste containing a heavy metal ion. 
Although apoE-rich HDL has the ability to bind to a heparin column in the presence of 
buffer containing Mg2+ or Ca2+, in a preliminary study we found that the amount of 
bound HDL increased dependent upon the divalent cation concentration. Therefore, we 
were unable to identify a suitable analytical condition for the selective separation of 
apoE-rich HDL using the heparin column (unpublished data). Alternatively, 
cation-exchange columns exhibit some similar properties to heparin, which functions as 
a cation exchanger owing to its high content of anionic sulfate groups. Hirowatari et al. 
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reported previously a separation method for major serum lipoproteins (HDL, LDL, and 
very low density lipoprotein (VLDL)) but not HDL subfractions using a cation-exchange 
column with eluents containing Mg2+ [32]. Therefore, we selected and used 
cation-exchange chromatography to isolate the apoE-rich HDL subfraction from total 
HDL.  
In the present study, the amount of HDL bound to the cation-exchange column 
increased dependent on the Mg2+ concentration in buffer A and reached a plateau at 
20–40 mM Mg2+ (Fig. 1C, D). Under these analytical conditions, approximately 90% of 
the HDL-apoE was eluted in the bound fraction (peak 2 in Fig. 1B). Analysis of the 
apoE-rich HDL fraction (bound HDL) by SDS-PAGE confirmed the presence of apoE as 
well as apoA-I, a major protein component of HDL (Fig. 2A). The ratio of apoE to apoA-I 
was higher in apoE-rich HDL compared to apoE-poor HDL (Table 1). The 
gel-permeation HPLC analysis also revealed that the particle size of isolated apoE-rich 
HDL was larger compared to that of apoE-poor HDL (Table 1 and Fig. 2B). These results 
indicate that HDL-apoE distributes predominantly to larger-sized HDL particles 
containing apoA-I, consistent with previous reports [14,29]. These biochemical 
characteristics of apoE-rich HDL support the validity of our method for the specific 
separation of apoE-rich HDL. Therefore, our method is more reliable and useful than 
the recently published homogeneous method [12] that lacks the ability to isolate 
apoE-rich HDL particles and to clarify their biological functions. 
With respect to analytical precision, our PEG-column method produced good 
within-day precision with CVs less than 3.52 and 0.45% for apoE-rich and apoE-poor 
HDL-C, respectively. Good linearity was observed in apoE-rich HDL-C levels from 1.0 to 
15 mg/dl (Fig. 3), indicating a marked advantage in the analysis of samples with low 
HDL-C concentrations. However, our method considerably underestimated apoE-rich 
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HDL-C levels compared to the double precipitation method, although significant 
correlations were produced by both methods (Fig. 4A). Notably, our method did not 
measure all of the apoE-containing HDL because approximately 10% of the HDL-apoE 
passed through the cation-exchange column (Fig. 1B, D). This finding may partially 
account for this disagreement. However, the apoE-rich HDL-C levels determined by the 
PEG-column method correlated more highly with the HDL-apoE levels compared to the 
relationship observed with the double precipitation method (Fig. 4B), indicating that 
the double precipitation method values might include a portion of the apoE-deficient 
HDL content as well as apoE-rich HDL. These comparisons indicate that the 
PEG-column method may have clinically important advantages compared with the 
previously reported methods. 
We found that apoE-rich HDL-C levels obtained by the PEG-column method 
correlated strongly with total HDL-C levels in accordance with a previous report [12]. A 
question thereby arises regarding whether apoE-rich HDL-C levels might represent a 
clinical biomarker independent of total HDL-C. However, several other clinical and 
biochemical variables also showed strong correlations with apoE-rich HDL-C (Table 3). 
It should be noted that plasma TG and adiponectin levels were found to be significant 
independent predictors of apoE-rich HDL, but not apoE-poor HDL, in multiple 
regression models (Table 4). Although total HDL-C levels often decrease under 
conditions of obesity and correlate positively with plasma adiponectin [33], the 
contribution of HDL subfractions with such variables has been little studied. Our 
current findings may provide a novel hypothetical concept of HDL subfractions whereby 
apoE-rich HDL might play more critical roles in TG metabolism and/or adipocyte 
dysfunctions as compared with apoE-poor HDL. 
ApoE-rich HDL particles obtained using the PEG-column method were larger in size 
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and their cholesterol levels exhibited a significant positive correlation with adiponectin, 
which is derived from adipose tissue, supporting our previous study that showed a 
negative correlation of the large-size HDL subclass with the visceral fat area [34]. 
Maeda et al. reported that the level of small, dense LDL-C showed a negative 
correlation with the large, buoyant HDL2 subfraction but not with small, dense HDL3 
[35]. Our data may partially support this study because apoE-rich HDL, that has an 
overlapping density with HDL2, showed a strong positive correlation with LDL size as 
compared to apoE-poor HDL in a simple regression analysis. After adjustment for TG, 
adiponectin, gender, and age, the positive association disappeared between apoE-rich 
HDL-C and LDL size but remained significant between the apoE-rich/apoE-poor HDL-C 
ratio and LDL size (Table 3). These results indicate that the compositional distribution 
of HDL subfractions might exhibit a more meaningful linkage to LDL size than the 
amount of total HDL.  
There was no significant difference in apoE-rich HDL-C levels between patients with 
and without >50% stenosis. However, the present study disclosed a significant 
correlation between apoE-rich HDL-C and other lipid markers of coronary risk. The 
reason for the insignificant difference in terms of stenosis may be related to the small 
number of patients studied. In addition, HDL fractions, including apoE-rich HDL-C, did 
not significantly correlate with CCS. CCS is a prognostic factor of coronary artery 
disease independent from other risk factors, including lipid markers of coronary risk. 
In conclusion, the PEG-column method established in our laboratory demonstrated 
high reproducibility and reliability for the determination of cholesterol in two HDL 
subfractions, apoE-rich and apoE-poor HDL. The two HDL subfractions displayed 
various significant correlations with several other lipid-related biomarkers involved in 
an atherogenic lipoprotein profile including plasma TG and adiponectin. These findings 
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indicate potential roles of adipose tissue in modulating HDL heterogeneity and of the 
distinct involvement of HDL subfractions in energy metabolism. Our separating 
technique for apoE-rich HDL particles will, therefore, likely be useful to clarify their 
biological functions and metabolism in human, animal, and cell culture studies. 
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Figure legends  
 
Fig.1. Effect of the Mg2+ concentration in running buffer A on HDL separation. 
Cholesterol (A) and apoE (B) distributions separated by cation-exchange 
chromatography of the PEG supernatant using buffer A containing 0 or 40 mM 
magnesium acetate. Bound HDL was eluted with buffer B containing 1.0 M sodium 
acetate. The unbound and the bound HDL fractions correspond to peaks 1 and 2, 
respectively. Percentage areas of peak 2 in the cholesterol (C) and the apoE (D) patterns 
are plotted as a function of Mg2+ concentrations in buffer A. 
 
Fig.2. Apolipoproteins and particle size of purified apoE-HDL. (A) Ten microliters of 
purified apoE-rich HDL (20 mg/dl cholesterol), apoE-poor HDL (20 mg/dl cholesterol), or 
VLDL (30 mg/dl cholesterol) were analyzed on 12% SDS-PAGE under reducing 
conditions. Proteins were stained by CBB R-250. (B) Ten microliters of purified 
apoE-rich HDL (8.2 mg/dl cholesterol), apoE-poor HDL (37 mg/dl cholesterol), or whole 
serum (161 mg/dl cholesterol) were analyzed by gel-permeation HPLC. The mean 
particle size was 14.2 nm for apoE-rich HDL (with the peak eluted at 32.5 min) and 11.2 
nm for apoE-poor HDL (with the peak eluted at 34.8 min). 
 
Fig.3. Linearity of the PEG-column method for total HDL-C (peak 1 + peak 2), 
apoE-poor HDL-C (peak 1), and apoE-rich HDL-C (peak 2). Chromatographic peak 
areas are plotted as a function of the expected cholesterol values of serially diluted PEG 
supernatants. Mean values are plotted from duplicate experiments. 
 
Fig.4. Scatter plots for apoE-rich HDL-C. (A) Comparison of apoE-rich HDL-C obtained 
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by the double precipitation and the PEG-column methods. (B) Correlations between 
apoE contents in HDL (HDL-apoE) and apoE-rich HDL-C obtained by the double 
precipitation (○) and the PEG-column (●) methods. 
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Table 1. Chemical composition of apoE-rich and apoE-poor HDL 
  
apoE-rich HDL 
 
apoE-poor HDL 
Lipid (%) 
 
75.4  ± 1.8  
 
53.6  ± 2.6  
 
Free cholesterol (%) 8.1  ± 0.6  
 
3.3  ± 0.2  
 
Cholesterol ester (%) 22.9  ± 2.8  
 
20.0  ± 1.4  
 
Phospholipid (%) 38.1  ± 2.3  
 
27.3  ± 1.1  
 
Triglyceride (%) 6.2  ± 1.8  
 
3.0  ± 0.5  
         
Protein (%) 24.6  ± 1.8  
 
46.4  ± 2.6  
 
apoA-I (%) 9.9  ± 2.0  
 
35.1  ± 2.1  
 
apoA-II (%) 4.4  ± 1.0  
 
10.9  ± 0.8  
 
apoE (%) 10.4  ± 1.3  
 
0.3  ± 0.4  
         
Particle size (nm) 14.8  ± 0.4  
 
10.8  ± 0.2  
ApoE-rich and apoE-poor HDL were purified from 4 healthy and normolipidemic subjects. Composition is expressed as weight 
percentage of major lipids and proteins. Values are means ± SD (n = 4).  
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Table 2. Clinical and biochemical characteristics of the study population 
 
All 
 
Female 
 
Male 
 
P value 
number of patients 36 
 
21 
 
15 
  
Age (years) 71.5  ± 6.0  
 
72.4  ± 5.9  
 
70.3  ± 6.1  
 
0.317 
BMI (kg/m
2
) 23.5  ± 3.7   
23.8  ± 4.3  
 
23.2  ± 2.7  
 
0.689 
TG (mg/dl) 130.9  ± 53.5  
 
128.6  ± 62.0  
 
134.1  ± 40.5  
 
0.768 
TC (mg/dl) 210.0  ± 47.8  
 
219.1  ± 50.3  
 
197.2  ± 42.3  
 
0.178 
LDL-C (mg/dl) 116.4  ± 41.5  
 
121.5  ± 42.7  
 
109.2  ± 40.1  
 
0.387 
HDL-C (mg/dl) 67.4  ± 17.1  
 
71.9  ± 17.6    61.2  ± 14.7  
 
0.063 
apoE- rich HDL-C (mg/dl) 3.5 ± 1.4 
 
3.8 ± 1.5 
 
3.0 ± 1.0 
 
0.067 
HDL-apoA-I (mg/dl)  144.0 ± 30.4  147.5 ± 26.8  139.3 ± 35.3  0.433 
HDL-apoA-II (mg/dl) 30.7 ± 6.0  30.2 ± 4.9  31.4 ± 7.5  0.544 
LDL size (nm) 27.1  ± 0.9  
 
27.3  ± 0.9  
 
26.9  ± 0.9  
 
0.188 
HDL size (nm) 11.1  ± 0.6  
 
11.3  ± 0.5    10.9  ± 0.6  
 
0.022 
              
Leptin (ng/ml) 8.3  ± 12.7  
 
12.5  ± 15.4  
 
2.5  ± 1.8  
 
0.008 
Adiponectin (μg/ml) 8.6  ± 7.8  
 
10.2  ± 9.3  
 
6.3  ± 4.5  
 
0.140 
Total calcium score 178.6  ± 274.7  
 
134.0  ± 230.4  
 
240.9  ± 325.2  
 
0.256 
> 50% stenosis 12 (33.3%) 
 
6 (28.6%) 
 
6 (40.0%) 
 
0.499 
              
Smoking 4 (11.1%) 
 
1 (4.8%) 
 
3 (20.0%) 
 
0.287 
        
Diabetes mellitus 6 (16.7%) 
 
3 (14.3%) 
 
3 (20.0%) 
 
0.677 
Hypertension 19 (52.8%) 
 
9 (42.9%) 
 
10 (66.7%) 
 
0.192 
Hyperlipidemia 19 (52.8%) 
 
9 (42.9%) 
 
10 (66.7%) 
 
0.192 
        
Statin 10 (27.8%) 
 
5 (23.8%) 
 
5 (33.3%) 
 
0.709 
Oral hypoglycemic or insulin 5 (13.9%) 
 
3 (14.3%) 
 
2 (13.3%) 
 
>0.999 
Antihypertensive 14 (38.9%) 
 
7 (33.3%) 
 
7 (46.7%)  
 
0.499 
BMI, body mass index.  
P value (male vs. female) judged by the Student’s t or Chi-squared test. Values are means ± SD.
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Table 3. Correlation between HDL subfractions and clinical and biochemical variables. 
 
apoE-poor HDL-C (mg/dl) apoE-rich HDL-C (mg/dl) apoE-rich / apoE-poor HDL-C ratio 
Age (years) −0.093  −0.075 −0.080 
BMI (kg/m
2
) −0.152  −0.180 −0.151 
eGFR (ml/min/1.73m
2
)  0.168  0.204 0.142 
Total calcium score  −0.040  −0.038 −0.022 
apoE-poor HDL-C (mg/dl)  1.000  0.901** 0.433** 
apoE-rich HDL-C (mg/dl)  0.901** 1.000 0.752** 
apoE-rich/apoE-poor HDL-C ratio  0.433** 0.752** 1.000 
TG (mg/dl) −0.523** −0.646** −0.511** 
TC (mg/dl)  0.435** 0.384* 0.200 
HDL-C (mg/dl)  0.968** 0.904** 0.467** 
LDL-C (mg/dl)  0.258  0.259 0.198 
HDL size (nm)  0.598** 0.630** 0.391* 
LDL size (nm)  0.257  0.472** 0.508** 
Leptin (ng/ml) −0.007  −0.079 −0.081 
Adiponectin (μg/ml)  0.440** 0.476** 0.358* 
HDL-apoA-I (mg/dl)   0.784** 0.652** 0.208 
HDL-apoA-II (mg/dl)  0.537** 0.381* 0.054 
HDL-apoE (mg/dl)  0.718** 0.884** 0.815** 
BMI, body mass index; eGFR, estimated glomerular filtration rate.  
Values are Spearman’s correlation coefficients (n = 36).  
*P <0.05, **P <0.01. 
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Table 4. Multiple regression analysis 
  variable beta coefficient P adjusted R
2
 
apoE-rich HDL-C TG (mg/dl) −0.395  0.030  
 
log adiponectin (μg/ml)   0.349  0.040  
 
gender −0.184  0.175  
 
age (years) −0.128  0.350  
 
LDL size (nm)  0.077  0.617  
 
   
0.486  
apoE-poor HDL-C log adiponectin (μg/ml)   0.359  0.063  
 
TG (mg/dl) −0.326  0.109  
 
age (years) −0.219  0.164  
 
gender −0.179  0.247  
 
LDL size (nm) −0.017  0.923  
 
    
0.330  
log (apoE-rich/apoE-poor HDL-C ratio) 
  
LDL size (nm)  0.343  0.048  
 
TG (mg/dl) −0.291  0.137  
 
log adiponectin (μg/ml)   0.172  0.346  
 
gender −0.081  0.584  
 
age (years) −0.043  0.774  
 
      0.376  
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